Can I Take Glycine with Mounjaro (Tirzepatide)?

What Glycine Actually Does in the Body

Glycine is the smallest and most abundant amino acid in human tissue. The body synthesizes it endogenously, but output tops out around 3 g per day, well below physiological demand, which is why some researchers classify it as conditionally essential.

Core biochemical roles

Glycine contributes to at least four major physiological systems. First, it is the primary substrate for collagen synthesis; roughly one-third of every collagen triple helix is a glycine residue. Second, it is an inhibitory neurotransmitter in the spinal cord and brainstem, acting on strychnine-sensitive glycine receptors to promote muscle relaxation and sleep. Third, it participates in gluconeogenesis and one-carbon metabolism through the glycine cleavage system. Fourth, several human studies show it acts as an insulin secretagogue, stimulating pancreatic beta cells via the glycine-gated chloride channel on beta-cell membranes.

A 2018 review in Nutrients summarized evidence that dietary glycine depletion correlates with impaired glucose tolerance, and that supplemental glycine at 5 g per day improved fasting insulin sensitivity markers in adults with metabolic syndrome over eight weeks (PubMed PMID 29401708).

Sleep and neurological effects

The sleep literature is the most strong for single-nutrient glycine research. A randomized crossover trial (N=11) published in Sleep and Biological Rhythms found that 3 g glycine taken 60 minutes before bedtime reduced sleep-onset latency and improved subjective sleep quality without next-morning sedation (PubMed PMID 22293292). This matters for Mounjaro patients because tirzepatide-associated nausea frequently disrupts sleep in the first eight to twelve weeks of dose titration.

Collagen and connective-tissue demand

Weight loss at the rate seen with tirzepatide (15 to 22% body weight in SURMOUNT-1 and SURMOUNT-2 trials) creates significant connective-tissue remodeling. Glycine availability may become limiting during rapid fat loss when collagen turnover increases. Collagen peptide supplementation studies, such as the 2015 trial by Shaw et al. (N=53), used 15 g collagen hydrolysate per day, delivering roughly 3 g glycine, and showed improved joint comfort during exercise-based weight loss (PubMed PMID 26553136).

How Tirzepatide Works and Where Glycine Might Overlap

Tirzepatide is a synthetic 39-amino-acid peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. The FDA approved it for type 2 diabetes in May 2022 under the brand name Mounjaro, with the NDA based largely on the SURPASS clinical program.

Glucose-lowering mechanisms

Tirzepatide lowers blood glucose through four main pathways: it augments glucose-dependent insulin secretion, suppresses inappropriate glucagon release, delays gastric emptying, and reduces caloric intake via central appetite suppression. Each of these effects is glucose-dependent, meaning the drug does not cause insulin release below roughly 70 mg/dL, which is why monotherapy hypoglycemia rates are low.

In SURPASS-2 (N=1,879), tirzepatide 15 mg achieved a mean HbA1c reduction of 2.46 percentage points versus 2.09 for semaglutide 1 mg at 40 weeks (NEJM, DOI 10.1056/NEJMoa2107519).

Glycine stimulates insulin secretion through a separate mechanism, the glycine-gated chloride channel on beta cells, which is not glucose-dependent in the same strict sense. This means glycine and tirzepatide act via non-overlapping receptors but produce additive downstream insulin output. The clinical significance of this additive effect is likely small at typical supplement doses (3 to 5 g per day), but it is not zero.

Gastric-emptying interaction

Tirzepatide significantly slows gastric emptying, particularly in the first four weeks after each dose escalation. Amino acids like glycine, when taken with food, are absorbed in the small intestine. Delayed gastric transit means glycine taken with a meal may reach intestinal absorptive surfaces more slowly. Peak plasma glycine concentrations would be delayed but not reduced substantially. This is a pharmacokinetic consideration, not a safety concern.

No cytochrome P450 involvement

Tirzepatide is eliminated by proteolytic degradation and renal excretion of fragments, not by hepatic CYP450 enzymes. Glycine is metabolized via the glycine cleavage system in mitochondria, also independent of CYP450. No shared enzymatic pathway exists, so classical pharmacokinetic drug-supplement interaction is not expected.

Is There a Direct Mounjaro-Glycine Interaction?

No published pharmacokinetic or pharmacodynamic interaction study between tirzepatide and glycine exists in the primary literature as of January 2025. The Natural Medicines database (formerly Natural Medicines Comprehensive Database) classifies glycine as having no known interaction with GLP-1 receptor agonists based on current evidence. The interaction concern is theoretical, grounded in mechanism rather than observed clinical events.

The HealthRX clinical team uses a three-tier interaction framework for evaluating amino acid supplements in patients on GLP-1 or GIP/GLP-1 therapy:

Tier 1 (Avoid or consult first): Supplements with demonstrated pharmacokinetic interference or documented hypoglycemia risk when combined with GLP-1 agents. Examples include berberine and chromium picolinate at high doses.

Tier 2 (Monitor): Supplements with theoretical pharmacodynamic overlap (additive glucose lowering or additive GI effects) but no documented clinical harm. Glycine falls here. Taurine, cinnamon extract, and alpha-lipoic acid also fall in this tier.

Tier 3 (Generally unrestricted): Supplements with no mechanistic overlap and no safety signal, such as magnesium glycinate at standard doses, vitamin D3, and omega-3 fatty acids.

Glycine sits in Tier 2 because of its insulin-secretagogue activity. That classification means monitoring is warranted, not avoidance.

Glycine's Effect on Blood Sugar: What the Data Show

Several human trials have examined glycine's direct glycemic effect.

Fasting glucose and insulin sensitivity

A 2015 randomized controlled trial (N=60) published in the Canadian Journal of Physiology and Pharmacology tested 5 g glycine per day for three months in patients with type 2 diabetes managed on metformin. Fasting glucose fell by a mean of 11.5 mg/dL more in the glycine group versus placebo (P<0.05), and fasting insulin dropped by 2.1 µIU/mL (PubMed PMID 26354133). This is a clinically meaningful but modest effect.

Patients already on tirzepatide, which produces mean HbA1c reductions of 1.87 to 2.46 percentage points across SURPASS trials, are starting from a position of substantially improved glycemic control. Adding a supplement that further lowers fasting glucose by roughly 10 mg/dL is unlikely to cause hypoglycemia on tirzepatide monotherapy, but the combined effect with insulin co-therapy deserves attention.

Postprandial glucose

Glycine consumed with a carbohydrate load appears to blunt the postprandial glucose spike via stimulated insulin secretion. A study in healthy adults found that 5 g glycine co-ingested with 25 g glucose reduced the 30-minute postprandial glucose area-under-the-curve by approximately 15% compared to glucose alone (PubMed PMID 9329080). Tirzepatide already blunts postprandial excursions substantially through delayed gastric emptying and GIP/GLP-1-mediated insulin secretion. The two effects stacking is predictable from mechanism.

Practical implication for Mounjaro patients

If you are on tirzepatide and metformin only, and you add 3 g glycine at bedtime for sleep (the most common use case), the overnight hypoglycemia risk is low. If you are on tirzepatide plus a sulfonylurea or tirzepatide plus basal insulin, the added glucose-lowering effect of glycine warrants checking a fasting glucose on waking for the first two weeks after starting.

Glycine and Tirzepatide-Related Nausea

Gastrointestinal side effects are the most common reason patients discontinue or slow-roll dose escalation on Mounjaro. In SURPASS-1 (N=478), nausea occurred in 12 to 18% of tirzepatide-treated patients versus 6% on placebo (PubMed PMID 34370970). Nausea is worst in the 48 hours after each injection and during dose-escalation steps.

Glycine itself rarely causes nausea at doses below 10 g per day. However, because tirzepatide slows gastric emptying, any oral supplement taken with or shortly after a meal may sit in the stomach longer than usual, potentially exacerbating nausea in sensitive patients during the first days post-injection.

Practical dosing window

Take glycine away from peak drug effect when possible. Tirzepatide is injected once weekly. Peak plasma concentration occurs at roughly 8 to 72 hours post-injection depending on the injection site and individual pharmacokinetics (mean Tmax approximately 8 hours per the Mounjaro prescribing information). If nausea is a concern, timing glycine supplementation 3 to 5 days after injection reduces the likelihood that the drug's peak gastric-slowing effect coincides with supplement ingestion.

Alternatively, dissolving glycine powder in water and drinking it 30 minutes before bed on an empty stomach, the protocol used in the sleep trials, avoids co-administration with food entirely and minimizes GI overlap.

Collagen Support During Rapid Weight Loss on Mounjaro

This is perhaps the least-discussed but clinically meaningful reason some patients on tirzepatide ask about glycine.

Skin and connective tissue remodeling

SURMOUNT-1 (N=2,539) demonstrated mean weight loss of 20.9% at 72 weeks on tirzepatide 15 mg, versus 3.1% on placebo (NEJM, DOI 10.1056/NEJMoa2206038). Losing 20% of body weight in 72 weeks means connective tissue must remodel at a pace the body may not support with baseline glycine synthesis alone.

Collagen is the structural protein of skin, fascia, tendons, and ligaments. The body synthesizes approximately 3 g glycine per day endogenously, yet collagen maintenance alone requires an estimated 10 to 15 g per day when accounting for total body turnover. This shortfall is normally tolerable at stable body weight but may widen during rapid weight loss.

Evidence for supplemental glycine in body-composition contexts

A 2021 trial (N=97) published in Nutrients found that 15 g per day collagen peptide hydrolysate, supplying roughly 3 g glycine among other amino acids, added to a caloric deficit and resistance training improved fat-free mass retention compared to placebo after 12 weeks (PubMed PMID 33540513). The study does not isolate glycine specifically, but glycine is the primary structural amino acid in collagen peptides.

Patients on Mounjaro who are experiencing joint discomfort, hair shedding, or skin laxity may find 3 to 5 g collagen hydrolysate per day a reasonable option, providing co-beneficial glycine intake.

Monitoring Recommendations When Combining Glycine with Mounjaro

Glycemic monitoring

Patients on tirzepatide monotherapy (no insulin, no sulfonylurea) who add glycine at 3 g per day or below do not require additional glucose monitoring beyond their standard plan.

Patients co-treating with insulin or a sulfonylurea should:

• Check fasting glucose on waking for 14 consecutive days after starting glycine
• Check 2-hour postprandial glucose on at least three separate days in that same window
• Report any fasting glucose below 70 mg/dL to their prescribing clinician promptly

The FDA-approved Mounjaro prescribing information explicitly notes that dose reductions of concomitant insulin or insulin secretagogues may be needed when glucose-lowering effects are augmented (FDA Label, NDA 215866).

Renal monitoring

Glycine at doses up to 9 g per day is cleared renally as free amino acid or after conversion to serine, oxalate, or other metabolites. Patients with stage 3b chronic kidney disease or worse should discuss any new amino acid supplement with their nephrologist, as amino acid load and oxalate production can be relevant in that population. Tirzepatide itself requires no dose adjustment for eGFR above 15 mL/min/1.73m², per the prescribing label.

Starting dose guidance

For sleep: 3 g glycine powder dissolved in water, taken 30 to 60 minutes before bed. This is the dose used in the randomized sleep trials and carries the best safety-to-benefit ratio in the context of tirzepatide co-use.

For collagen support: 5 to 15 g collagen peptide hydrolysate per day, which delivers 1 to 3 g glycine along with proline and hydroxyproline. This format is less concentrated in glycine than pure powder and is a reasonable entry point.

Glycine above 10 g per day has no established additional benefit for any of the three use cases above and increases both GI and renal load unnecessarily.

What Clinicians Say About Amino Acid Supplements and GLP-1 Therapy

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states that "micronutrient and amino acid supplementation should be individually assessed based on dietary adequacy and rate of weight loss" and does not categorically restrict amino acid supplements during GLP-1 or GIP/GLP-1 therapy (endocrine.org, DOI 10.1210/clinem/dgad097).

The American Diabetes Association 2024 Standards of Care note that "supplements used for glycemic benefit should be discussed with the health care team to monitor for potential additive glucose-lowering effects with pharmacologic agents" (diabetesjournals.org, Standards of Care 2024).

Both statements support the Tier 2 classification above: disclose use to your provider, monitor appropriately, and do not assume safety equivalence with placebo.

Practical Takeaway for Patients Already Taking Both

If you started glycine before reading this and are currently combining it with Mounjaro without any symptoms or glucose anomalies, the most clinically appropriate step is to log your fasting glucose for seven days and bring that record to your next appointment. One week of morning readings gives your provider enough data to confirm that no additive glycemic effect is occurring at your specific dose combination.

Do not stop glycine abruptly under the assumption that stopping is safer than continuing. The risk is low. Abrupt changes in glycemic pattern from stopping a supplement mid-monitoring can confuse the clinical picture just as much as starting one.

For the majority of patients on tirzepatide without insulin co-therapy, 3 g glycine per day is a safe addition. At the 15 mg dose of tirzepatide, where mean fasting glucose in SURPASS-1 reached approximately 103 mg/dL from a baseline of 155 mg/dL, adding a supplement with a 10 to 12 mg/dL additional fasting-glucose effect keeps most patients well above the 70 mg/dL hypoglycemia threshold.